Expert Insights: Investigational ADCs Safety Profiles
September 25th 2024Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.
Read More
Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
September 18th 2024Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.
Read More
Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
September 18th 2024Panelists discuss how management and monitoring for pneumonitis and cardiotoxicity in trastuzumab deruxtecan (T-DXd) is similar to trastuzumab emtansine (T-DM1), while also emphasizing the need for awareness of adverse effects such as peripheral neuropathy, thrombocytopenia, and hepatotoxicity, along with strategies for their management and when to consider therapy modifications.
Read More
Expert Insights: SG Adverse Events Management including Alopecia & Nausea
September 4th 2024Panelists discuss how to manage side effects of sacituzumab govitecan (SG), including counseling on alopecia, proactive management strategies, routine antiemetic premedications, and adjustments for chemotherapy-induced nausea and vomiting, as well as recommended breakthrough antinausea medications for home use.
Read More
Navigating SG-related Diarrhea
September 4th 2024Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.
Read More
Expert Perspectives on the Management of SG-Related Neutropenia
August 28th 2024This discussion focuses on strategies to manage neutropenia associated with SG, including the use of prophylactic growth factors and timing of their administration, comparing management approaches between clinicians.
Read More
ADCs in Breast Cancer: Mechanism of Action, and Components
August 21st 2024Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.
Read More
Overview of Current ADCs in Breast Cancer
August 21st 2024Medical experts review the currently available antibody-drug conjugates for breast cancer, including Sacituzumab govitecan (Trop-2 directed ADC), Kadcyla (ado-trastuzumab emtansine, T-DM1, HER2-directed ADC), and Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd, HER2-directed ADC).
Read More
Dr. Rugo on the Optimal Setting for Biosimilar Evaluation
November 20th 2018Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the optimal setting for biosimilar evaluation.
Read More
Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer
November 14th 2018Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses resistance to CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.
Read More
Dr. Rugo Discusses the Equivalency of Trastuzumab Biosimilars
November 3rd 2018Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the equivalency that has been demonstrated with biosimilars for trastuzumab (Herceptin).
Read More
Dr. Rugo Discusses a Comparative Review of Trastuzumab Biosimilars
October 27th 2018Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses a comparative review of trastuzumab (Herceptin) biosimilars.
Read More
Dr. Rugo Discusses Late Recurrence in HR+ Breast Cancer
October 31st 2017Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.
Read More
Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer
October 14th 2016Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses MYL-1401O, a proposed biosimilar for trastuzumab (Herceptin), in patients with HER2-positive metastatic breast cancer.
Read More